GlassScriptPhysician profile
David R Fawks
NPI 1922094937
$8,721.35
in general payments reported to CMS, 2019-2025
24 companies · $2,789 in 2025
The $2,789 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $1,622 · 2023: $1,761 · 2024: $2,311 · 2025: $2,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,825 · Education: $35.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,824.65 |
| Education | $35.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.41 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,089.93 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,016.40 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $833.08 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $570.78 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $554.87 | 2022-2025 | Spravato |
| Alkermes, INC. | $544.22 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $444.11 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Almatica Pharma LLC | $335.45 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $319.48 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $307.09 | 2021-2025 | Rexulti |
| Corium, LLC | $228.42 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $221.20 | 2022-2025 | Trintellix |
| Noven Therapeutics, LLC | $188.30 | 2024-2025 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $185.72 | 2023-2025 | Qelbree, Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $185.71 | 2024-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $172.79 | 2022-2025 | Quviviq, Quviviq |
| Bausch Health US, LLC | $125.59 | 2021-2025 | Aplenzin, Wellbutrin |
| Merck Sharp & Dohme LLC | $111.04 | 2022-2023 | Belsomra |
| Neos Therapeutics, LP | $31.66 | 2024-2025 | Adzenys Xr-Odt |
| Tris Pharma INC | $24.08 | 2024 | Dyanavel Xr |
| Validus Pharmaceuticals LLC | $19.66 | 2025 | Equetro |
| Tonix Medicines, INC. | $16.09 | 2025 | Tonmya |
| Tms Neurohealth Centers INC. | $11.27 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fawks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.